Variant Summary
- Also known as
- RS113488022,VAL600GLU,V640E,VAL640GLU
- HGVS
- NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A
- Variant Type(s)
- missense_variant
- Evidence Items
- 95
Evidence Level Distribution
Level A: 5Level B: 61Level C: 17Level D: 12
Evidence Items
Showing CIViC evidence rows where gene = BRAF and variant = V600E.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| B | Prognostic | Does Not Support | Poor Outcome | Papillary Thyroid Carcinoma | 5 | |
| B | Prognostic | Supports | Poor Outcome | Colorectal Cancer | 5 | |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Vemurafenib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Skin Melanoma | Vemurafenib | 5 |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Dabrafenib,Trametinib | 5 |
| B | Prognostic | Supports | Poor Outcome | Papillary Thyroid Carcinoma | 5 | |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Dabrafenib,Trametinib | 5 |
| B | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Encorafenib,Binimetinib,Cetuximab | 5 |
| B | Diagnostic | Supports | Positive | Papillary Thyroid Carcinoma | 5 | |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Trametinib,Dabrafenib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Encorafenib,Cetuximab | 5 |
| B | Diagnostic | Supports | Positive | Hairy Cell Leukemia | 4 | |
| A | Predictive | Supports | Sensitivity/Response | Solid Tumor | Trametinib,Dabrafenib | 4 |
| A | Predictive | Supports | Sensitivity/Response | Low Grade Glioma | Dabrafenib,Trametinib | 4 |
| B | Predictive | Does Not Support | Sensitivity/Response | Colorectal Cancer | Vemurafenib | 4 |
| C | Predictive | Supports | Sensitivity/Response | Papillary Thyroid Carcinoma | Vemurafenib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Vemurafenib,Cobimetinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Vemurafenib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Vemurafenib,Irinotecan,Cetuximab | 4 |
| B | Prognostic | Supports | Poor Outcome | Colorectal Cancer | 4 | |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Trametinib | 4 |
| B | Prognostic | Supports | Poor Outcome | Papillary Thyroid Carcinoma | 4 | |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Trametinib,Dabrafenib | 4 |
| B | Predictive | Supports | Resistance | Colorectal Cancer | FOLFOX-4 Regimen,Cetuximab | 4 |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Vemurafenib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Skin Melanoma | Trametinib,Dabrafenib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Vemurafenib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Panitumumab,Trametinib,Dabrafenib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Trametinib,Dabrafenib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Anaplastic Thyroid Carcinoma | Trametinib,Dabrafenib | 4 |
| B | Prognostic | Supports | Poor Outcome | Colorectal Cancer | 4 | |
| B | Prognostic | Supports | Poor Outcome | Colorectal Cancer | 4 | |
| B | Prognostic | Supports | Poor Outcome | Childhood Low-grade Glioma | 4 | |
| B | Predictive | Supports | Sensitivity/Response | Langerhans Cell Sarcoma | Vemurafenib | 4 |
| B | Predictive | Does Not Support | Resistance | Colorectal Cancer | Cetuximab,Panitumumab | 4 |
| B | Predictive | Supports | Sensitivity/Response | Papillary Thyroid Carcinoma | Vemurafenib | 4 |
| B | Prognostic | Supports | Poor Outcome | Papillary Thyroid Carcinoma | 4 | |
| B | Prognostic | Supports | Poor Outcome | Melanoma | 3 | |
| B | Prognostic | Supports | Poor Outcome | Papillary Thyroid Carcinoma | 3 | |
| B | Prognostic | Supports | Poor Outcome | Papillary Thyroid Carcinoma | 3 | |
| B | Prognostic | Supports | Poor Outcome | Papillary Thyroid Carcinoma | 3 | |
| D | Predictive | Supports | Sensitivity/Response | Cancer | Cobimetinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Cancer | Dabrafenib,Trametinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Low Grade Glioma | Vemurafenib | 3 |
| B | Predictive | Supports | Resistance | Colorectal Cancer | Cetuximab | 3 |
| B | Predictive | Supports | Reduced Sensitivity | Colorectal Cancer | Dabrafenib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Vemurafenib,Cetuximab,Gefitinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Skin Melanoma | Vemurafenib | 3 |
| B | Predictive | Does Not Support | Sensitivity/Response | Colorectal Cancer | Panitumumab,Vemurafenib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | GDC-0879,Dactolisib | 3 |
Page 1 of 2